The Heart Outcomes Protection Evaluation (HOPE) study: Relevance to ophthalmological practice?

Eye

Volumn 14, Issue 1, 2000, Pages 1-2

  Barnett, A H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; RAMIPRIL;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; EDITORIAL; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY;

EID: 0034051176     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/eye.2000.1     Document Type: Editorial

References (3)

1. The Heart Outcomes Prevention Evaluation Study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
2. The Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus; results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
3. Chaturvedi N, Sjolie AK, Stephenson JM et al. Effect of lisinopril on progression of retinopathy in people with type I diabetes. Lancet 1998;351:28-31.